首页> 外文期刊>Nephron >Improvement of nutritional status in patients receiving maintenance hemodialysis after correction of renal anemia with recombinant human erythropoietin.
【24h】

Improvement of nutritional status in patients receiving maintenance hemodialysis after correction of renal anemia with recombinant human erythropoietin.

机译:重组人促红细胞生成素纠正肾性贫血后接受维持性血液透析的患者营养状况的改善。

获取原文
获取原文并翻译 | 示例
           

摘要

Despite a large body of evidence showing the beneficial effects of successful treatment of anemia with recombinant human erythropoietin (EPO) in patients with end-stage renal disease, controversy remains as to whether EPO treatment of anemia can improve the nutritional status in patients on maintenance hemodialysis. This prompted us to conduct a prospective study in 41 hemodialysis patients with basal hemoglobin less than 9 g/dl. The dose of EPO was increased for 12 weeks to achieve the target hemoglobin concentration of 10 g/dl and then titrated in the following 12 weeks to maintain the target value. Nutritional status was assessed at baseline and after 6 months of follow-up, using the global protein-calorie malnutrition (PCM) index proposed by Bilbrey and Cohen. A low global PCM score indicates better nutrition. The results showed that hemoglobin values significantly increased from 8.7 +/- 0.8 g/dl at baseline to 10.7 +/- 0.5 g/dl in the 6th month (p < 0.001). No significant changes were observed in the normalized protein catabolic rate and Kt/V during the study period. Global PCM scores improved from 30.0 +/- 7.5 to 23.6 +/- 3.1 (p < 0.001) and paralleled the correction of anemia by EPO treatment. The data were consistent with a major improvement in the nutritional markers of relative body weight, triceps skinfold, midarm circumference, midarm muscle circumference, serum albumin, serum transferrin and total lymphocyte count in the 6th month as compared to baseline. The percentages of mild and moderate-severe PCM at baseline were 32 and 58%, respectively. These percentages were significantly reduced during the 6th month to 20 and 30%, respectively (p = 0.0004). In summary, correction of renal anemia with EPO improves the nutritional status in hemodialysis patients. A postulated mechanism is that EPO may exhibit anabolic effects, with a better utilization of ingested protein.
机译:尽管有大量证据表明重组人促红细胞生成素(EPO)成功治疗贫血对终末期肾病患者具有有益作用,但关于EPO贫血治疗能否改善维持性血液透析患者的营养状况仍存在争议。这促使我们对41名基础血红蛋白低于9 g / dl的血液透析患者进行了一项前瞻性研究。 EPO剂量增加12周以达到目标血红蛋白浓度10 g / dl,然后在接下来的12周内滴定以维持目标值。使用Bilbrey和Cohen提出的全球蛋白质热量营养不良(PCM)指数,在基线和随访6个月后评估营养状况。较低的整体PCM分数表明营养更好。结果表明,血红蛋白值从基线的8.7 +/- 0.8 g / dl显着增加到第6个月的10.7 +/- 0.5 g / dl(p <0.001)。在研究期间,未观察到归一化蛋白质分解代谢速率和Kt / V的显着变化。总体PCM评分从30.0 +/- 7.5改善到23.6 +/- 3.1(p <0.001),与EPO治疗纠正的贫血并行。与基线相比,该数据与第6个月相对体重,三头肌皮褶,中臂围,中臂肌围,血清白蛋白,血清转铁蛋白和总淋巴细胞计数的营养指标的重大改善相一致。基线时轻度和中度重度PCM的百分比分别为32%和58%。这些百分比在第6个月中分别显着降低至20%和30%(p = 0.0004)。总之,用EPO纠正肾性贫血可改善血液透析患者的营养状况。推测的机制是EPO可能显示出合成代谢作用,并更好地利用了摄入的蛋白质。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号